Register here
Christian Klingbeil
Partner, Deal Advisory - Valuation
KPMG AG Wirtschaftsprüfungsgesellschaft
+49 89 9282 1284 Christian
Klingbeil
Phone number
Current Issue:
The new edition of our newsletter on transactions in the global life sciences industry glances back at the significant deals that took place in H1 2024 and provides further insights on the industry’s market trends.
- Regardless of the persisting geopolitical uncertainties, including elevated interest rates, H1 2024 recorded M&A in a deal bracket ranging from transformative to smaller yet impactful transactions, as companies look to complement their portfolios to tackle the impending patent cliff.
- Consequently, heightened competition among buyers for high-quality assets resulted in elevated deal premiums, reflecting investors’ interest in making purchases despite concerns about sustained high levels of inflation.
- In addition, investors are adopting a tiered approach to prioritize their investments across therapeutic indications to recalibrate and diversify their portfolios through a mix of M&A and licensing strategies to merge scientific innovation and strategic imperatives.
- Specifically, emerging modalities such as radiopharmaceuticals, antibody drug conjugates, bispecific antibodies, and microbial therapeutics have garnered significant strategic interest from investors.
